Utilizing HealthTree ® Cure Hub’s Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 PandemicConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 치료법, [키워드] age analyzed Bacterial Cancer cancer patient Cell change changed changes Chemotherapy Comorbidities condition COVID-19 COVID-19 pandemic cure dose Evidence illnesses Immunocompromised indicated intravenous management Mortality Multiple Multiple myeloma Myeloma participated Patient patients precursor question Radiation real-world data reduce replaced required response risk susceptible total effect Treatment [DOI] 10.1182/blood-2021-150890 [Article Type] Conference abstract
Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic PeriodConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 치료법, [키워드] 95% confidence interval addition Affect age Analysis Anemia anemic Anxiety baseline baseline characteristics blueprint board cancer diagnosis change changes in clinical clinical feature Clinical outcome Cohort Community comparable competing concerning conducted COVID COVID-19 COVID-19 pandemic Cox proportional hazard Cyclophosphamide database death Delayed determine diagnosed Diagnosis download equity evaluated Evidence examined family member figure Follow-up funding hospital in-person visit initial ISS Kaplan-Meier curve Kidney disease kidney dysfunction Kidney function log-rank test mAb management measure monoclonal antibody Multiple Multiple myeloma Myeloma no difference North not significant notable observé pandemic Patient patients pattern Pearson performance status Period receive receiving regimen regimens Regression model risk SAS SAS Institute Sex Support table therapy thyme Travel Treatment treatment initiation type I variable Version was used [DOI] 10.1182/blood-2021-148998 [Article Type] Conference abstract
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy혈액 학적 악성 종양 및 COVID -19 환자 877 명의 UKCCMP 코호트의 주요 결과 : 최근 화학 요법 또는 항 -CD20 요법에 비해 중요한 요소로서 질병 조절Observational Study Published on 2021-11-102022-08-31 Journal: British Journal of Haematology [Category] MERS, 바이오마커, 임상, [키워드] 95% CI 95% confidence interval adjusted age Analysis anti‐CD19 association Cancer cancer treatments cancer type Chemotherapy Cohort Comorbidities COVID‐19 Cytotoxic chemotherapy death diagnosed disease Disease activity disease control Haematological cancer haematological malignancies haematological malignancy high risk highest increased mortality increased risk investigated limitation malignancy Mortality Multivariate analysis Myeloma observational study Patient patients with haematological progressive disease prospective observational study receiving risk SARS‐CoV‐2 SARS‐CoV‐2 infection Severe infection Sex therapy Treatment [DOI] 10.1111/bjh.17937 PMC 바로가기 [Article Type] Observational Study
Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple MyelomaResearch Letter Published on 2021-11-012022-10-31 Journal: Emerging Infectious Diseases [Category] COVID-19, MERS, SARS, [키워드] acute respiratory syndrome Ad26.COV2.S capillary capillary leak syndrome Clarkson disease Clinical finding coronavirus coronavirus disease COVID-19 COVID-19 vaccine died higher risk history leak Monoclonal Gammopathy Multiple Multiple myeloma Myeloma receiving respiratory infections SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Shock suggested systemic systemic capillary leak syndrome the patient vaccination Vaccine Vaccines viruses [DOI] 10.3201/eid2711.211723 PMC 바로가기 [Article Type] Research Letter
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesCOVID-19는 혈액암 환자에서 SARS-CoV-2에 대한 손상된 항체 반응을 유발합니다Clinical Trial Published on 2021-11-012022-09-11 Journal: British Journal of Haematology [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% confidence interval Analysis antibody response against Care Cell Chemoimmunotherapy COVID-19 detectable Efficacy elicit haematological malignancies high mortality HM patient HM patients IgG IgG test immune dysfunction indicate investigated leukemia lymphoid lymphoma malignancy multivariable logistic regression myeloid Myeloma negative patients Neoplasms Patient patients patients with haematological PCR-positive performed plasma Plasma cell plasma cell neoplasms rate of seroconversion SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 PCR Seroconversion Serologically serum antibodies Treatment vaccination Withdrawal [DOI] 10.1111/bjh.17704 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view다발성 골수종 환자의 코로나19: 단기 및 장기 관점에서 SARS-CoV-2에 대한 세포 및 체액 면역Case Reports Published on 2021-10-182022-09-10 Journal: Journal of Molecular Medicine (Berlin, Germany) [Category] MERS, SARS, 진단, 치료기술, [키워드] Affect affecting anti-SARS-CoV-2 antibody antibody levels Antibody titer Antibody titers CD4+ T-cell cell activation cellular Cellular immune response Clinical management Combination Continuous Course COVID-19 Decision-making deficiency detectable diagnosed with COVID-19 Disease progression help humoral Humoral immunity Hypogammaglobulinemia IgA IgG antibodies IgM IgM and IgG immune response Immunity immunodeficiency immunological immunomodulatory drugs Immunosuppression infections information inhibitors Innate immunity Isolation lenalidomide Measures memory monoclonal antibodies monoclonal antibody Multiple Multiple myeloma Myeloma neutralizing antibody titers neutropenia Patient performed positive proteasome receiving recommendation remained robust SARS-CoV-2 supplementary material supportive therapy T cell T cell activation T-cell tested the patient therapy treated Treatment underlying disease virus-neutralizing virus-neutralizing antibody [DOI] 10.1007/s00109-021-02114-x PMC 바로가기 [Article Type] Case Reports
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)혈액 악성 악성 종양이있는 성인 환자의 COVID-19 감염 : 유럽 혈액학 협회 조사 (Epicovideha)Clinical Trial Published on 2021-10-142022-08-13 Journal: Journal of Hematology & Oncology [Category] MERS, SARS, 임상, 진단, [키워드] active malignancy acute myeloid leukemia Adult patients adverse outcome adverse outcomes age Analysis analyzed baseline characteristics cause of death chronic cardiac disease chronic lymphoid leukemia Clinical management Combination complications correlated COVID-19 COVID-19 infection COVID-19 patient COVID-19 patients death died EHA EPICOVIDEHA Epidemiology European Hematology Association group hematological Hematological malignancies Hematological malignancy hematology high risk HM patient HM patients Hospitalized ICU ICUs IMPROVE include increase in intensive care unit intensive care units laboratory-confirmed Laboratory-confirmed COVID-19 leukemia Liver disease lymphoproliferative lymphoproliferative diseases malignancy Mortality mortality rate mortality risk multivariable analysis Myelodysplastic syndrome myelodysplastic syndromes Myeloma myeloproliferative malignancies myeloproliferative malignancy Non-Hodgkin Lymphoma p value Patient patients patients with HM predictor reduced renal impairment reported Result risk factor Risk factors SARS-CoV-2 disease SARS-CoV-2 disease 2019 second wave significantly smoking supplementary material supported survey the patient working [DOI] 10.1186/s13045-021-01177-0 PMC 바로가기 [Article Type] Clinical Trial
P-130: The impact of COVID-19 on the treatment regimens of myeloma and AL amyloidosis patientsConference abstract Published on 2021-10-012022-10-05 Journal: Clinical lymphoma, myeloma & leukemia [Category] 치료법, [키워드] administration amyloidosis Belgium Bone marrow Care Cell changes in conducted COVID-19 COVID-19 pandemic diagnosed Diagnosis Europe examined finding focus Frequency General population Germany group hcp healthcare Healthcare provider healthcare services hospital Iceland injection invasive Medicine Myeloma negatively affected Netherland one patient pandemic participant Patient Poland positive preference receiving reported researcher Result Romania Safe Side-effects Spain study participant subcutaneous injection suggested switching tablets took place Treatment treatment regimen virus was reduced [DOI] 10.1016/S2152-2650(21)02257-6 [Article Type] Conference abstract
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaReview article Published on 2021-10-012022-10-05 Journal: Transplantation and cellular therapy [Category] 비임상, [키워드] Annual CAR T-cell cellular therapy chimeric antigen receptor clinical Clinical trial design conducted Cytometry disease Endpoint Evolution flow cytometry hematology immune profiling Marrow meeting Minimal residual disease molecular Multiple Multiple myeloma Myeloma network Next-generation sequencing Profiling progression residual Society T-cell Testing Thursday Transplant workshop [DOI] 10.1016/j.jtct.2021.05.027 [Article Type] Review article
MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology CenterConference abstract Published on 2021-09-012022-10-05 Journal: Clinical lymphoma, myeloma & leukemia [Category] 유전자 메커니즘, [키워드] addition administration age Analysis Antibiotics association cardiovascular risk center Characteristics Chronic kidney disease clinical Cohort Comorbidities cough country COVID-19 COVID-19 infection Critical demonstrated Diabetes Mellitus diagnosed diagnosed with COVID-19 died Dyspnea elevated epidemiological Fever Hematological malignancy hematology high mortality Hospitalization Hospitalized hospitalized patients Hydroxychloroquine hyperlipidemia Hypogammaglobulinemia Hypoxemia Immunosuppression incidence Inflammatory marker inflammatory markers initial symptom Laboratory laboratory characteristics Lung disease lung infiltrate male Male sex mandatory mechanical ventilation median median age Mild MM Mortality Most patient Multiple Multiple myeloma multiple organ failure Myeloma obesity Patient patients performed Preliminary data reported required Result Retrospective study serological response severity significantly the disease viral infection [DOI] 10.1016/S2152-2650(21)01959-5 [Article Type] Conference abstract